U.S. Markets open in 2 hrs 39 mins

Argos says independent committee suggests stopping carcinoma study

Feb 22 (Reuters) - Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee has recommended the company to discontinue its late-stage trial for the treatment of metastatic renal cell carcinoma.

The company said the IDMC concluded that the company's combination treatment was unlikely to demonstrate a statistically significant improvement, the primary goal of the study.

(Reporting by Akankshita Mukhopadhyay in Bengaluru)